Search Results - tlr7%2f8

1 Results

Sort By:

Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1

Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer. However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer. For those cancers associated with these limited immune systems, there remains a need...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, De Yang, Michael Bustin

Keywords(s): Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics